Form 4: Terns Pharmaceuticals Chief Medical Officer Emil Kuriakose Granted Stock Options
SEC Form 4
Terns Pharmaceuticals' Chief Medical Officer, Emil Kuriakose, was granted stock options for 485,000 shares on January 30, 2025.
Summary
- Emil Kuriakose, the Chief Medical Officer of Terns Pharmaceuticals, was granted stock options to purchase 485,000 shares of common stock.
- The options have an exercise price of $4.64 per share.
- The grant date was January 30, 2025.
- The options vest over four years, with 25% vesting on the first anniversary of January 1, 2025, and the remainder vesting monthly thereafter.
- The options expire on January 29, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative news.
Positives
- The granting of stock options aligns the interests of the Chief Medical Officer with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align their interests with company performance.
Comparison to Industry Standards
- Stock option grants are a standard practice for executive compensation in the biotech and pharmaceutical industries.
- The vesting schedule of 25% on the first anniversary and the remainder monthly is a typical vesting structure.
- The exercise price of $4.64 is specific to Terns Pharmaceuticals and would need to be compared to the current market price of the stock to assess its value.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the Chief Medical Officer to contribute to the company's success.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/01/2025 | Vesting Commencement Date for the stock options. |
| 01/30/2025 | Date the stock options were granted. |
| 02/03/2025 | Date the Form 4 was signed. |
| 01/29/2035 | Expiration date of the stock options. |
Keywords
stock options, executive compensation, insider trading, Terns Pharmaceuticals, Emil Kuriakose, Chief Medical Officer, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.